Stockwinners Market Radar for June 06, 2019 - Earnings, Upgrades downgrades, option trades, Best Stock Advisory Service

20:32 EDT United Steelworkers authorizes strike against Arconic - The United Steelworkers said that members of local unions representing Arconic workers at the company's facilities in Davenport, Iowa, Lafayette, Ind, and Massena, N.Y., have granted their negotiating committee the authority to implement a strike if necessary at those three facilities covered by a master agreement. The strike authorization votes were conducted during meetings at each location over the course of the past several weeks. USW members have continued to work under the terms and conditions of a contract that was set to expire on May 15, 2019, when the USW and Arconic agreed to a temporary extension, subject to termination by either party with 24-hours' notice. USW International Vice President Tom Conway, who chairs the union committee, said that negotiations between the USW and Arconic broke off with the company demanding major economic and non-economic concessions that the union considers excessive and unnecessary.

18:46 EDT Fly Intel: After Hours Movers - UP AFTER EARNINGS: Zumiez (ZUMZ) up 18.9%... Beyond Meat (BYND) up 15.5%... Zoom Video (ZM) up 10.7%... Guess (GES) up 1.4%. ALSO HIGHER: CRISPR Therapeutics (CRSP) up 10.1% after entering expanded collaboration deal with Vertex... Endologix (ELGX) up 4.1% after announcing reinstatement of CE Mark for Nellix System... Caesars Entertainment (CZR) up 4.1% on WSJ speculation company is near deal to merge with Eldorado Resorts (ERI) up 0.8%. DOWN AFTER EARNINGS: DocuSign (DOCU) down 20.6%... Domo (DOMO) down 18.5%... Ollie's Bargain Outlet (OLLI) down 4.1%. ALSO LOWER: Xeris Pharma (XERS) down 6.1% after disclosing extension for Gvoke PDUFA date from FDA. Movers as of 18:30ET.

17:21 EDT Vertex to acquire Exonics Therapeutics for $245M - Vertex (VRTX) announced that the company is enhancing its gene editing capabilities to develop novel therapies for Duchenne Muscular Dystrophy and Myotonic Dystrophy Type 1 by expanding its collaboration with CRISPR Therapeutics (CRSP) and acquiring Exonics Therapeutics, a privately held company focused on creating "transformative" gene editing therapies to repair mutations that cause DMD and other severe neuromuscular diseases. Under the terms of this strategic collaboration and license agreement, Vertex will pay $175M upfront for the exclusive worldwide rights to CRISPR Therapeutics' existing and future intellectual property including foundational CRISPR/Cas9 technology, novel endonucleases, single and double cut guide RNAs, and AAV vectors for DMD and DM1 gene editing products. For the DMD program, Vertex is responsible for all research, development, manufacturing, and commercialization activities and all related costs. For the DM1 program, Vertex and CRISPR will share research costs for specified guide RNA research to be conducted by CRISPR, and Vertex is responsible for all other research, development, manufacturing, and commercialization costs. Under the terms of the acquisition, Vertex will acquire all outstanding shares of Exonics, which will become a separate wholly-owned subsidiary of Vertex. Exonics equity holders are eligible to receive payments of approximately $1B, including $245M upfront and potential future payments based primarily upon the successful achievement of specified development and regulatory milestones for the DMD and DM1 programs.

17:11 EDT Graco VP Jeffrey Johnson sells over $730K in company shares - Graco VP Jeffrey Johnson disclosed in a filing that he had sold 15,000 shares of company shares at $48.85 per share on June 6. The total transaction value of the sale was $732,750.

17:06 EDT Beyond Meat says revenue guidance 'very conservative' - Says making "aggressive" push for European growth.

16:52 EDT Beyond Meat sees Q2, Q3 representing strongest contributions of the year - Says has tripled manufacturing capacity. Says seeing increased demand across retail and food service channels. Sees Q2 and Q3 to represent strongest net revenue and profit contributions of the year. Sees Q3 greater than Q2.

16:46 EDT Beyond Meat says still in 'very early innings' of growth - Says still in "very early innings" of growth. Says has just 2% household penetration in the U.S. Says has begun to respond to "significant demand" in Europe. Says vows flexibility as new opportunities appear.

16:41 EDT Beyond Meat says 'well-positioned' for long term growth - Says well-positioned for long term growth in the U.S. and globally. Says reported "strong" first quarter. Says saw positive trends in key profit metrics in Q1. Comments taken from Q1 earnings conference call.

16:38 EDT Zoom Video jumps almost 13% after Q1 report, guidance exceed expectations - Shares of Zoom Video are up 12.5% or $9.93 per share to $89.36 per share in after hours trading.

16:34 EDT Zumiez jumps 17% after Q1 reports beats estimates - Shares of Zumiez are up 17% or $3.16 to $21.83 per share in after-hours trading.

16:32 EDT Dixie Group says 'unaware of any material change' to account for unusual trading - "The Dixie Group does not comment normally on unusual trading activity. However, the company management wishes to confirm that it is unaware of any material change in its operations that would account for today's unusual trading volume."

16:27 EDT Zoom Video says customers contributing $100M + in TTM revenue, up 120% y/y

16:20 EDT Guess reports Q1 Americas retail comp sales up 5% in constant currency - Reports Q1 Europe retail comp sales up 8% in constant currency. Reports Q1 Asia comp sales down 10% in constant currency.

16:19 EDT Novan regains compliance with Nasdaq - Novan announced it has received notification from Nasdaq that the company has regained compliance with Listing Rule 5450. This rule requires a minimum $50M market value of listed securities in order to maintain a listing on Nasdaq. The company previously received a non-compliance notification from Nasdaq on January 14. As part of that notification, the company was informed that compliance would need to be achieved within 180 calendar days, or no later than July 15.

16:17 EDT Mercury Systems receives $8.2M order - Mercury Systems announced it received an $8.2M follow-on order from a leading defense prime contractor for rugged, ultra-compact memory devices integrated into an advanced airborne command, control and intelligence application. The order was booked in Q4 and is expected to be shipped over the next several quarters.

16:16 EDT Nike names Ratnakar Lavu global chief digital information officer - Nike (NKE) announced that Ratnakar Lavu will become the company's first Global Chief Digital Information Officer, effective June 17. He will report to Eric Sprunk, Nike Chief Operating Officer. Lavu will lead all of Nike's global technology functions across the enterprise with responsibility for accelerating new digital capabilities for Nike. Lavu most recently was the Chief Technology and Information Officer at Kohl's (KSS), where he led all of IT, digital and consumer technology. Prior to joining Kohl's, Lavu was Chief Technology Officer at Redbox.

16:11 EDT Beyond Meat up 5.5% after reporting Q1 earnings, giving FY19 guidance

16:10 EDT Vail Resorts reports season pass sales through May 28 up 9% in units - Season pass sales through May 28 for the upcoming 2019/2020 North American ski season increased approximately 9% in units and 13% in sales dollars as compared to the period in the prior year through May 29, 2018, excluding sales of all military pass products in both periods. Pass sales include Stevens Pass and Triple Peaks pass sales in both periods and are adjusted to eliminate the impact of foreign currency by applying an exchange rate of $0.74 between the Canadian dollar and U.S. dollar to the current period and the prior period for Whistler Blackcomb pass sales.

16:09 EDT Xeris Pharmaceuticals announces extension for Gvoke PDUFA date from FDA - Xeris Pharmaceuticals announced that the FDA has extended the initial Prescription Drug User Fee Act, or PDUFA, goal date for its review of the company's new drug application, or NDA, seeking marketing approval of Gvoke by three months. The new PDUFA goal date is September 10. The company received a notification letter from the FDA on June 5, which states that the company's recent submission in response to an information request from the FDA constitutes a major amendment to the NDA, and therefore, the FDA is extending the goal date by three months to provide time for a full review of the submission. According to FDA's current PDUFA performance goals, an FDA decision to extend the review period typically is limited to situations where review of the new information could address an outstanding issue and lead to approval in the current review cycle. The FDA has not requested additional clinical data in connection with the Gvoke NDA, and the company has provided all additional information that FDA has requested to date.

16:06 EDT Four Corners Property Trust acquires 5 Red Lobster properties for $18.5M - Four Corners Property Trust announces the acquisition of five Red Lobster restaurant properties in Illinois, Michigan, Ohio, Pennsylvania and South Carolina for $18.5M. The five newly acquired properties are under a single, triple-net master lease which includes eight other Red Lobster properties previously acquired by FCPT in November 2017 and December 2018.

16:06 EDT Clovis names Ginger Graham new board of directors chair - Clovis Oncology announced the appointment of Ginger L. Graham as Board Chair to Clovis' Board of Directors, following the retirement of former Board Chair Dr. M. James Barrett. Ginger L. Graham has served as a member of the Company's board of directors since 2013. She is the former President and CEO of Amylin Pharmaceuticals, a biopharmaceutical company based in San Diego, CA focused on diabetes. Previously, Graham was Group Chairman, Office of the President for Guidant Corporation.

16:03 EDT Endologix announces reinstatement of CE Mark for Nellix System - Endologix Inc. announced that the EC Certificate of Conformity for the Nellix EndoVascular Aneurysm Sealing System has been reinstated by GMED, the EU Notified Body for the Nellix System. The reinstatement followed an assessment of clinical evidence. "We continue to believe that the Nellix System has the potential to transform the treatment of patients with infra-renal abdominal aortic aneurysms," said Matt Thompson MD, Chief Medical Officer of Endologix, Inc. "This therapy continues to generate positive results when used in patients that conform to the anatomical indications for use. We are delighted that the available data supports the reinstatement of our CE mark, and we look forward to utilizing this technology to improve the patient experience and drive better outcomes." As previously disclosed, the Nellix System will be made available for use at approved centers in a post-market clinical investigational setting outside the USA. Within the USA, the Nellix System remains an investigational device as part of the EVAS2 study. The company does not expect this reinstatement to impact its previously communicated financial guidance for 2019.

16:01 EDT Xeris Pharmaceuticals Inc trading halted, news pending

15:41 EDT GlaxoSmithKline says FDA approves two new methods for administering Nucala - GlaxoSmithKline announced that the U.S. Food and Drug Administration has approved two new methods for administering Nucala, an autoinjector and a pre-filled safety syringe, for patients or caregivers to administer once every four weeks, after a healthcare professional decides it is appropriate. "This is the first anti-IL5 biologic to be licensed in the US for at-home administration, and the first respiratory biologic to be approved for administration via an autoinjector. This approval will give healthcare professionals and people living with severe eosinophilic asthma or the rare disease eosinophilic granulomatosis with polyangiitis the option for Nucala to be administered outside of a clinical setting by a patient or caregiver after their healthcare professional agrees this approach is appropriate. The original lyophilised powder version remains available for administration by a healthcare professional," the company said.

15:10 EDT FDA approves Senseonics' Eversense Continuous Glucose Monitoring System - In a filing, the FDA's Center for Devices and Radiological Health disclosed it issued an approval order for Senseonics' Eversense Continuous Glucose Monitoring System. Reference Link

15:03 EDT Graco Launches new radial piston air motors for industrial paint kitchens - Graco has expanded its line of paint agitators to include radial piston air motor driven agitators. Tested extensively in different conditions in the lab and the field, the new radial piston air motor typically uses 30 to 50 percent less compressed air than comparable rotary vane motors at low to medium speeds. "Compressed air represents the highest energy cost for many factories, so lowering compressed air use can mean significant savings," said Henry Zeng, Graco Product Marketing Manager for the Industrial Products Division. "Agitator motors usually use the most air of any industrial paint kitchen equipment. This makes agitator efficiency a top way to conserve air and save money." Graco's radial piston air motor works most efficiently at low to medium speeds.This makes it ideal for mixing low to medium viscosity material in direct drive mode.

14:11 EDT Aeterna Zentaris downsizing German workforce, sees $800K severance cost - Aeterna Zentaris announced that it is reducing the size of its German workforce and operations to more closely reflect the company's ongoing commercial activities in Frankfurt.This restructuring will affect eight employees in Frankfurt, Germany and is expected to result in approximately $800,000 of severance costs that is expected to be paid by January 31, 2020. The company is also providing an update on the previously disclosed securities class action lawsuit pending in the U.S. District Court for the District of New Jersey, brought on behalf of shareholders of the company. The lawsuit alleges violations of the Securities Exchange Act of 1934 in connection with allegedly false and misleading statements made by the defendants between August 30, 2011 and November 6, 2014 regarding the safety and efficacy of Macrilen and the prospects for the approval of the Company's New Drug Application for the product by the FDA. In February 2018, the U.S. court granted a motion for class certification in the case, and this week the U.S. Third Circuit Court of Appeals dismissed an appeal of that certification motion that had been brought by the Company. The company considers the claims that have been asserted in the lawsuit to be without merit and is vigorously defending against them. The company cannot, however, predict at this time the outcome or potential losses, if any, with respect to this lawsuit. The company continues to believe that substantially all of the costs for its defense will be borne by the insurers who provide directors' and officers' liability insurance to the company, subject to policy limits.

13:59 EDT Barnes & Noble jumps after WSJ says going private deal could come in days - Elliott Management is the leading bidder in the auction of Barnes & Noble and a deal to take the company private could be reached in the coming days, Wall Street Journal reports, citing sources. Shares of Barnes & Noble jumped 15%, or 71c, to $5.30 following the report.

13:19 EDT Trump administration serious about big tech investigations, Fox's Gasparino says - Fox Business' Charles Gasparino said via Twitter that, "SCOOP: Industry execs say Trump Administration is serious about investigations into big tech; DOJ examining ads search engines in @Google [GOOG; GOOGL] probe, how @Apple [AAPL] deals w app developers; FTC will likely be looking at privacy issues involving @Facebook [FB] and @amazon [AMZN] more now @FoxBusiness [...] ALSO: Sources says big tech outfits also "lawyering-up" in the face of serious government probes into @Google @Apple @facebook @amazon." Reference Link

13:01 EDT Victory Capital reports 10.12% passive stake in AngioDynamics - In a regulatory filing, Victory Capital disclosed a 10.12% stake in AngioDynamics, which represents about 3.76M shares. The filing does not allow for activism.

12:50 EDT Twitter says refreshing rules with 'simple, clear language' - Del Harvey, VP, Trust and Safety, Twitter, said in a blog post: "Our rules exist to help keep everyone using Twitter safe and ensure they can participate freely in the public conversation. Over time, we've added new rules and updated existing ones, but these changes eventually made our rules confusing and difficult to understand. So today, we're refreshing our rules with simple, clear language and reorganizing them into high-level categories: safety, privacy and authenticity. We've also added detail around other policies, including election integrity, platform manipulation and spam. We've gone from about 2,500 words to under 600. In 280 characters or less, each rule clearly describes exactly what is not allowed on Twitter. New categories - safety, privacy, and authenticity - mean our rules are organized thematically, so you can find the information you're looking for more quickly. We're refreshing rule pages to have more information, including examples, step-by-step instructions about how to report, and details on what happens when we take action. Everyone who uses Twitter should be able to easily understand what is and is not allowed on the service. As part of our continued push towards more transparency across every aspect of Twitter, we're working to make sure every rule has its own help page with more detailed information and relevant resources, with abuse and harassment, hateful conduct, suicide or self-harm, and copyright being next on our list to update. Our focus remains on keeping everyone safe and supporting a healthier public conversation on Twitter." Reference Link

12:40 EDT Google says customers can buy games individually from Stadia Base - Google (GOOG) also announced Stadia Base, which allows users to buy games they want on an individual basis without a subscription. The company added that the Founder's Edition is only available for a limited time. In terms of games, Google unveiled Stadia trailers for Ubisoft's (UBSFY) "Assassin's Creed Odyssey," Square Enix's "Shadow of the Tomb Raider" and "Final Fantasy XV," Bethesda's "Wolfenstein: Youngblood," Bungie's "Destiny 2," and others.

12:36 EDT Google announced Stadia Pro at $9.99 a month, Founder's Edition for $129 - At its Stadia event, Google (GOOG) announced the pricing options for Stadia, including Stadia Pro, which for $9.99 per month will have Google regularly add content to a user's Stadia library. The company also announced Stadia Founder's Edition, coming to 14 countries at launch, which will include a limited edition night blue Stadia controller, a Chromecast Ultra, three months of Stadia Pro for the buyer and a friend, first opportunity to create a Stadia name, and the complete "Destiny 2" experience. The Founder's Edition will cost $129 and is available for pre-order now. "Destiny 2" is made by Bungie was originally published by Activision Blizzard (ATVI).

12:35 EDT Xynomic announces dosing first patient in Phase 1/2 lymphoma trial - Xynomic Pharmaceuticals (XYN) announced that it has dosed the first patient in a Phase 1/2 trial that combines abexinostat with ibrutinib in patients with relapsed/refractory mantle cell lymphoma or relapsed/refractory diffuse large B-cell lymphoma at Memorial Sloan Kettering Cancer Center. This trial will enroll approximately 40 patients to assess the safety and efficacy of the combination in patients with r/r MCL or r/r DLBCL. This trial will also explore the biologic predictors of response and resistance to dual B-cell receptor and histone deacetylase inhibition. Janssen Biotech (JNJ) is providing ibrutinib as part of the study, with Xynomic providing abexinostat and funding support for the trial being conducted at MSK, the company said.

12:18 EDT Spotify signs multi-year podcast deal with President Barack and Michelle Obama - President Barack Obama and Michelle Obama's production company, Higher Ground, announced a partnership with Spotify to produce podcasts exclusive to the platform. "The Obamas formed Higher Ground to produce powerful stories to entertain, inform and inspire, and to lift up new, diverse voices in the entertainment industry," it said in a statement. Spotify, which recently surpassed 100 million Premium subscribers and has more than 217 million monthly active users, will distribute the podcasts to audiences across the globe. Under the Higher Ground partnership, President and Mrs. Obama will develop, produce, and lend their voices to select podcasts, connecting them to listeners around the world on wide-ranging topics. The multi-year agreement will be with Higher Ground Audio, an expansion of the Higher Ground production company that will oversee the move into podcasts. "We've always believed in the value of entertaining, thought-provoking conversation," President Obama said. "It helps us build connections with each other and open ourselves up to new ideas. We're excited about Higher Ground Audio because podcasts offer an extraordinary opportunity to foster productive dialogue, make people smile and make people think, and, hopefully, bring us all a little closer together."

12:11 EDT Cogent Communications VP Timothy O'Neill sells almost $235K in company shares - Cogent VP Timothy O'Neill disclosed in a filing that he had sold 4,000 shares of company stock at an average price of $58.62 per share on June 6. The total transaction value of the sale was $234,480.

12:07 EDT Google's Harrison says Larian's 'Baldur's Gate III' coming to Stadia - Google's (GOOG) Stadia head Phil Harrison said that it has established an "incredible" lineup of games to be available on Stadia at launch. In addition to Ubisoft (UBSFY), Stadia will offer Larian Studios' "Baldur's Gate III," which was announced at the event. Says Stadia "years in the making" at Google. Says goal of Stadia is to make gaming more accessible for everyone. Says highest possible quality gaming experience on Stadia is "remarkable," and can be used by people with internet speeds of 35 Mbps. Says connection speeds of 10Mpds can steel stream games at 720p video quality. Comments taken from Google's Stadia Connect event.

12:00 EDT IDT Corp rises 8.9% - IDT Corp is up 8.9%, or 57c to $6.95.

12:00 EDT Ciena rises 25.4% - Ciena is up 25.4%, or $9.11 to $44.99.

11:50 EDT Verint: Neuberger Berman to withdraw nominations of three directors to board

11:12 EDT Tesla jumps after Electrek says North America sales on pace for record - Shares of Tesla (TSLA) are up nearly 7% to $209.81 in early trading after a report last night from an electric vehicle focused website claimed that the company was offering employees new bonuses in order to deliver all the vehicles it had recently sold in a "record" quarter. According to Electrek's Fred Lambert, Tesla executives held a call yesterday with sales and delivery managers in North America to discuss the fact that the company had already delivered 33,000 vehicles in North America this quarter and that it was aiming to deliver another 33,000 vehicles in June. To help the company reach its goal, the Tesla managers offered significant bonuses to sales and delivery employees, the report claims, citing sources. The Fly notes that yesterday JMP Securities analyst Joseph Osha noted that monthly U.S. registration data published by InsideEVs, another electric vehicle focused site, show that more Model 3s were registered in April and May than during all of the first quarter. Reference Link

10:48 EDT Eros sinks 54% after addressing credit downgrade of subsidiary - Shares of Eros International are sinking after the company earlier today provided clarification regarding a credit rating downgrade at its majority owned subsidiary, Eros International Media Limited. The Company offered the following statement: "Eros International PLC and all of its subsidiaries have met and continue to meet all debt service commitments. The Company retains the full faith and confidence of our lenders. We will be releasing our audited Fiscal year-end 2019 results on July 15th, 2019, at 8:30 am Eastern Time, full details to follow." Shares of Eros, an Indian entertainment company, are down 54%, or $3.94, to $3.36 in morning trading.

10:44 EDT Eros International trading halted, volatility trading pause

10:16 EDT FleetCor slips as Citron says company sold over $100M in 'phony carbon offsets' - Shares of FleetCor (FTL) are under pressure on Thursday after Citron Research called the company the "largest clean energy fraud in U.S. history" in a recently published report, and said it has "fraudulently sold well over $100M in phony carbon offsets." LARGEST 'CLEAN ENERGY FRAUD': In a recently published report, Andrew Left's Citron Research called FleetCor the "largest Clean Energy Fraud in U.S. history." "While FleetCor has used excessive fees to grow earnings, the recent growth of the company is not from a fee and not from the highly publicized beyond fuel program but rather from a nefarious and hidden scheme called the "Clean Advantage" program," the report reads, adding that "This is an outright 'green fraud' that has brought FleetCor to their Philidor moment and should lead to the immediate resignation of CEO Ronald Clarke." Citron also pointed out that the company "doesn't dare" to discuss the impact of this program, but its CEO has "validated this last year" by referring to the new "zero emissions" program as a key driver of growth. "Yet, this program does not appear in any of the company's investor presentations or corporate filings," the report added. "The amount paid into the 'Clean Advantage' program to date is at a minimum $100M and growing, making this THE LARGEST CLEAN ENERGY FRAUD in US. history. In layman's terms, FleetCor has sold enough phony carbon offsets to land their board of directors in jail for the rest of their lives." PRICE ACTION: In morning trading, shares of FleetCor have dropped over 4% to $240.65.

10:01 EDT Arthur J. Gallagher acquires MDV Wealth Planning, terms not disclosed - Arthur J. Gallagher & Co. announced the acquisition of Fox River Grove, Ill.-based MDV Wealth Planning. Terms of the transaction were not disclosed. Founded in 2014, MDV Wealth Planning sells and places life insurance products for clients of registered investment advisors, independent financial advisors, institutional brokers, life insurance professionals, and property/casualty agents and brokers.

10:00 EDT Cloudera falls -37.6% - Cloudera is down -37.6%, or -$3.31 to $5.50.

10:00 EDT ABM rises 7.7% - ABM is up 7.7%, or $2.88 to $40.16.

10:00 EDT Ciena rises 19.5% - Ciena is up 19.5%, or $7.00 to $42.88.

09:52 EDT Bombardier to provide 74 additional Twindexx Vario coaches to Israel Railways - Bombardier Transportation has signed a contract to provide 74 additional BOMBARDIER TWINDEXX Vario double-deck coaches to Israel Railways. This call-off is part of a framework agreement signed in October 2010 and is valued at approximately $166M. The delivery of the new coaches is scheduled to be completed by December 2021. The new order consists of eleven control cars for operation with TRAXX electric locomotives, also compatible with diesel locomotives, eleven intermediate coaches with dedicated space for people with reduced mobility and 52 trailer cars. "Michael Fohrer, President Central and Eastern Europe and Israel at Bombardier Transportation said, "We are very proud to have signed a seventh consecutive order with Israel Railways, a result of exemplary collaboration and customer satisfaction. It is testimony to the superior quality and reliable performance in customer service of all coaches delivered up to this point."

09:47 EDT At Home Group falls -41.3% - At Home Group is down -41.3%, or -$7.23 to $10.28.

09:47 EDT Just Energy rises 4.8% - Just Energy is up 4.8%, or 17c to $3.69.

09:47 EDT Ciena rises 16.6% - Ciena is up 16.6%, or $5.96 to $41.84.

09:29 EDT Hubbell Incorporated appoints Gerben Bakker COO - Hubbell Incorporated announced the appointment of Gerben Bakker to the role of president and COO. In his new role, Bakker will support David Nord, chairman and CEO. Bakker will be building on leading Hubbell Power Systems. After assuming the role of group President in 2014, Bakker led the business through 12 acquisitions and approximately doubled revenues over four years.

09:21 EDT Tableau down 1.5% after Google announces deal to buy Looker - Tableau (DATA) shares are down 1.5% to $119.80 in pre-market trading after Alphabet's (GOOGL) Google unit announced a deal to buy Looker for $2.6B in cash. Tableau offers an analytics platform that it said "empowers people of any skill level to work with data," while Google describes Looker as "a unified platform for business intelligence, data applications and embedded analytics."

09:19 EDT Rimini Street announces new subsidiary in Mexico - Rimini Street announced that it has expanded its Latin America operations with the launch of its new subsidiary, Rimini Street de Mexico, S. de R.L. de C.V., opening of its new office in Mexico City and hiring of staff. The company's investment is in response to its growing client base with operations in Mexico and accelerating local demand for its portfolio of award-winning, ultra-responsive enterprise software support services.

09:19 EDT Ciena says sees sales growth back to 6%-8% beyond FY19

09:12 EDT HomeStreet comments on preliminary offer from Dwight Capital - HomeStreet confirmed that its board has received Dwight Capital's letter conveying a preliminary non-binding offer of $60M for the company's Fannie Mae DUS Business, which is a subset of HomeStreet's multi-family mortgage lending business. Consistent with its fiduciary duties under applicable law, the board and management, together with outside advisors, will carefully evaluate Dwight Capital's preliminary offer, which is the first formal offer HomeStreet has received from Dwight Capital, publicly or privately. HomeStreet will act with expediency and respond to Dwight Capital in due course once the board has completed its evaluation.

09:10 EDT Google to acquire Looker for $2.6B in cash

09:08 EDT Casella Waste acquires three solid waste businesses - Casella Waste Systems announced that it has acquired three solid waste businesses with hauling, transfer and recycling operations in Maine, Massachusetts, and Vermont. All transactions closed in May 2019. The company acquired the assets of D & E Rubbish Removal, Inc., the assets of Bin Dump'n Trash, and the stock of TAM, Inc. and its wholly owned and related subsidiaries. In total, the company expects to generate approximately $11.5M of annualized revenues from these acquisitions. The company said, "Our acquisition pipeline remains robust with over $30M of annual revenues under letter of intent that we expect to close by the end of the third quarter, and we continue to be focused on efforts to drive cash flow growth across our footprint through disciplined strategic growth."

09:06 EDT Fly Intel: Pre-market Movers - HIGHER: ContraVir Pharmaceuticals (CTRV), up 120% after announcing findings from a preclinical study where CRV431, a novel cyclophilin inhibitor, decreased the extent of fibrosis in a second animal model of liver fibrosis. UP AFTER EARNINGS: Ciena (CIEN), up 18%... Stitch Fix (SFIX), up 26%. DOWN AFTER EARNINGS: Michaels (MIK), down 12%... At Home Group (HOME), down 37%... Kirkland's (KIRK), down 28%... Cloudera (CLDR), down 37%. ALSO LOWER: Kontoor Brands (KTB), down 1% after BofA Merrill Lynch analyst Heather Balsky started shares with an Underperform rating and $24 price target. The analyst expects the company's growth plan to miss expectations due to a tough retail environment and underinvestment in its Lee and Wrangler brands.

09:04 EDT Royal Caribbean sees impact of Cuba travel policy change on FY19 EPS 25c-35c - Royal Caribbean noted the U.S. government's policy change on travel to Cuba and provided a range for its financial impact. On June 4, the U.S. government announced that effective June 5th, authorized travel to Cuba under the People-to-People program is rescinded and travel to Cuba via cruise ships is prohibited. Therefore, effective June 5th, cruise ships will no longer be allowed to travel between the U.S. and Cuba. The company has changed the itineraries for its June 5th and June 6th departures and is determining alternate destinations for future sailings. The company estimates that the financial impact of this regulatory change is a reduction to the Adjusted EPS for 2019 in the range of 25c-35c per share. "While the affected sailings impact only 3 percent of our 2019 capacity, the extremely short notice period for this high yielding destination amplifies the earnings impact," said Jason T. Liberty, executive vice president and CFO. "The result of this policy change has created a short-term impact to our guests, operations and earnings; fortunately, we have many alternative and attractive destinations for our guests to choose from."

09:00 EDT Tabula Rasa HealthCare announces three-year agreement with Portugal's NHS - Tabula Rasa HealthCare announced a three-year agreement with Portugal's National Health Service, or NHS, Centro Hospitalar Lisboa Ocidental for DoseMe's proprietary dose optimization software, DoseMeRx.

08:53 EDT Discover CFO R. Mark Graf to retire in 2020 - Discover announced that R. Mark Graf, executive vice president and CFO, has informed the company of his intent to retire in 2020. Graf will remain in his current role until a successor is appointed to ensure that management and the board have the appropriate time to evaluate a full slate of candidates for the company's next CFO. Graf will participate in the process and will remain an employee of the company until early 2020 to ensure a smooth transition. The executive talent firm Crist Kolder Associates will be conducting the search for Graf's replacement.

08:35 EDT Health Insurance Innovations acquires TogetherHealth for $50M, 630,000 shares - Health Insurance Innovations announced the acquisition of all of the outstanding equity of the businesses known as TogetherHealth, a direct-to-consumer platform connecting individuals with U.S. insurance carriers through consumer acquisition and engagement primarily serving the over 65 insurance market. The transaction was consummated using a mix of cash, HIIQ stock and contingent consideration and is expected to be immediately accretive to the company's earnings. The purchase consideration, subject to certain adjustments, includes approximately $50M of cash and 630,000 shares of HIIQ Class A common stock, and a five-year earnout provision based on the future performance of the acquired businesses.

08:31 EDT ContraVir Pharmaceuticals announces findings from CRV431 preclinical study - ContraVir Pharmaceuticals announced findings from a preclinical study where CRV431, a novel cyclophilin inhibitor, decreased the extent of fibrosis in a second animal model of liver fibrosis. Fibrosis, or scarring, of the liver is a hallmark symptom of NASH that results in impaired liver function. Obeticholic acid, or OCA, a semi-synthetic bile acid analogue drug approved for the treatment primary biliary cholangitis, or PBC, and being evaluated in Phase 3 trials by another company, was used as a comparator drug in the study and did not decrease the extent of fibrosis in this study conducted by ContraVir. In this industry-standard model, liver fibrosis is induced in mice by administering carbon tetrachloride, or CCl4. In the preclinical study, CCl4-treated mice received either 50 mg/kg of CRV431; 10 mg/kg of OCA; or a vehicle control. All were administered orally, once daily for six weeks. Liver fibrosis was then quantified using sirius red staining to measure the amount of hepatic collagen, which accumulates in fibrosis. Compared to the control group, CRV431 reduced fibrosis scores by approximately 43%, whereas OCA did not demonstrate a statistically significant reduction in fibrosis. This trial, conducted at the Scripps Research Institute, is the fifth to demonstrate statistically significant anti-fibrotic efficacy of CRV431, but the first to use the CCl4 animal model. Previously, four separate, independent preclinical studies demonstrated similar effects of CRV431 in a STAM NASH model. In the STAM NASH model, liver fibrosis is induced in mice by administering streptozotocin, followed by a high fat diet beginning at three weeks of age and continuing for the duration of the study. All four studies showed statistically significant reductions in fibrosis scores. In the first study, conducted at the Stelic Institute in Japan, STAM NASH mice were administered CRV431 orally, once daily for three weeks at a dose of 20 mg/kg, which decreased the extent of fibrosis by 57% compared to vehicle control. In the second study, conducted at the Scripps Research Institute, STAM NASH mice were administered CRV431 orally, once daily for six weeks at a dose of 50 mg/kg, which decreased the extent of fibrosis by 46% compared to vehicle control. In the third study, conducted at the Scripps Research Institute, STAM NASH mice were administered CRV431 orally, once daily for 11 weeks at a dose of 50 mg/kg, which decreased the extent of fibrosis by 37% compared to vehicle control. In the fourth study, conducted at the Scripps Research Institute, STAM NASH mice were administered CRV431 orally, once daily for 10 weeks at a dose of 50 mg/kg but at a much later stage of disease. In this study, fibrosis was reduced by 44%, confirming CRV431 efficacy across a wide range of disease time points. ContraVir is developing CRV431 for NASH, fibrosis and other liver diseases such as viral hepatitis and hepatocellular carcinoma. A Phase 1, single ascending dose study of CRV431 was safe and well tolerated in humans.

08:18 EDT Alimera Sciences announces three-year follow-up data from Phase 3 Iluvien trial - Alimera Sciences announced three-year follow-up data from the Phase 3 clinical trial for Iluvien 190 micrograms intravitreal implant in applicator, for the prevention of relapse in recurrent non-infectious uveitis affecting the posterior segment of the eye, or NIPU. The data will support the company's planned launch of Iluvien for the NIPU indication in Europe during the second half of 2019. In the 129-patient prospective, randomized and masked clinical trial, patients received a single Iluvien implant or an active control sham injection and recurrence of NIPU was assessed based on the observation of specified NIPU symptoms or by active treatment by clinicians. The median time to first recurrence of NIPU was significantly longer in the Iluvien arm of the trial, compared to the control sham arm. The number of recurrences of uveitis was significantly lower in the Iluvien arm vs the sham arm over the 36 months. There was a significantly greater improvement from baseline in Best Corrected Visual Acuity, or BVCA, in the Iluvien treated arm compared to sham. IOP was well-controlled in both arms, mainly by IOP-lowering medication. Patients treated with Iluvien had a lower rate of surgery to reduce severe IOP compared to sham and a higher rate of cataract surgery compared to sham.

08:10 EDT BioCardia effects one-for-nine reverse stock split, plans for listing - BioCardia announced that a reverse stock split of its common stock, $0.001 par value, at a ratio of one-for-nine, is effective immediately. The company's common stock will begin trading on a split adjusted basis when the markets open under the new trading symbol (BCDAD) and in 20 business days, the trading symbol will revert back to the existing symbol. The company's common stock has been assigned a new CUSIP number in connection with the reverse stock split. As a result of the reverse split, each nine pre-split shares of common stock outstanding will automatically combine into one new share of common stock without any action on the part of the holders, and the number of outstanding common shares will be reduced from approximately 43.6M shares to approximately 4.8M shares. The reverse stock split will also apply to common stock issuable upon the exercise of the company's outstanding stock options and warrants for common stock. There is no change to the number of authorized shares under the company's certificate of incorporation, as amended. The common stock issued pursuant to the reverse stock split will remain fully paid and non-assessable. The reverse stock split will not affect the par value of the common stock. On April 4, the board of directors of the company approved the reverse stock split, subject to stockholder approval. A majority of stockholders approved the reverse split by written consent on April 5 in accordance with the company's current charter and bylaws. The primary goal of the reverse stock split is to increase the per share market price of the stock to meet the minimum share bid price requirements required to enable the company to list its common stock on either the Nasdaq or the New York Stock Exchange. The company has filed a registration statement on Form S-1 with the U.S. Securities and Exchange Commission relating to a proposed public offering of equity securities that it intends to consummate on or about the time of such listing.

08:08 EDT Mack-Cali Realty issues letter to stockholders on Board elections - Mack-Cali Realty issued a statement urging stockholders to vote "for all" of the company's 11 director nominees at the company's Annual Meeting of Stockholders scheduled for June 12. The statement says, among other things: "Bow Street Special Opportunities Fund XV, a New York based hedge fund, has nominated four candidates for election to the Board at the Annual Meeting (...) The Company believes that Bow Street has: Launched its proxy contest for the sole purpose of facilitating its self-interested proposal to acquire the company's premium assets as a lowball price or forcing a "fire sale" of the Company or its assets in order to make a quick profit on its recent investment; attempted to "greenmail" the Company by proposing to withdraw its director nominations if the Company agreed to sell certain assets to Bow Street at a "wholesale" price; and employed "bait and switch" tactics and deliberately mischaracterized facts throughout its campaign in an effort to disguise its self-serving agenda and distract and confuse Mack-Cali stockholders (...) a vote on the white proxy card "for all" of the Company's 11 highly qualified nominees is a vote in support of: the Mack-Cali Board's continued commitment to maximizing stockholder value, including its commitment to form a Strategic Review Committee, composed solely of independent directors, to conduct a comprehensive review of the Company's strategic direction to ensure that all available alternatives for continued stockholder value creation, including a potential sale of the Company, are carefully and thoughtfully considered; corporate governance best practices, including the Board's previously announced offer to add two of Bow Street's director nominees, MaryAnne Gilmartin and Frederic Cumenal, to the Board immediately after the Annual Meeting and, if they accept the offer, the Board's commitment to appoint both of them to the Strategic Review Committee; continued Board refreshment (...) and the continued execution of the Company's Waterfront Strategy and asset portfolio transformation, which Mack-Cali expects will accelerate earnings growth and narrow the gap between its NAV and stock price, and unlock significant value for stockholders within the next two years (...)"

08:07 EDT Michaels down 15.4% after reporting Q1 results, cutting FY19 EPS view

08:04 EDT SkyWest reports May block hours up 8.3% - SkyWest Airlines reported 124,404 block hours in May, an increase of 8.3% from May 2018. SkyWest Airlines' higher production was primarily due to the incremental E175 aircraft, CRJ900 aircraft and CRJ700 aircraft added to SkyWest Airlines' fleet since May 2018. Reports May departures up 8.7%, passengers up 11.7%, load factor up 1 pts to 83.9.

08:02 EDT Intelex announces agreement to be acquired by Industrial Scientific for $570M - Intelex announced that it has entered into a definitive agreement to be acquired by Industrial Scientific, a global leader in connected sensing technology and safety-as-a-service and wholly owned subsidiary of Fortive. Intelex will be acquired from JMI Equity and HarbourVest for approximately $570M. The transaction is expected to close late in the second quarter or early the third quarter, subject to customary closing conditions including regulatory approvals, upon which Intelex will be operated as a stand-alone company inside Industrial Scientific.

07:58 EDT Axovant announces six-month follow-up data from cohort of SUNRISE-PD trial - Axovant reported six-month follow-up data from the first dose cohort in the open-label, dose-escalation portion of the ongoing SUNRISE-PD Phase 2 trial of AXO-Lenti-PD for the treatment of Parkinson's disease. AXO-Lenti-PD was observed to be generally well tolerated, with no serious adverse events related to the product or the procedure and patients showed continued improvement from baseline across multiple measurements. In addition, the company is providing a pipeline update. At month six, the patients experienced an average improvement from baseline in UPDRS III OFF score of 17 points, representing an average improvement of 29%. Individual patient improvements at 6 months were 14 and 20 points, respectively. The patients experienced an average improvement of approximately 20 points from baseline on the UPDRS Part II OFF score, and an average improvement of 3 points from baseline on the UPDRS Part IV OFF score. The average levodopa equivalent daily dose, or LEDD, at baseline was 1117mg and at month six was 884mg, a decrease of 233 mg, or 21% from baseline. On the Rush Dyskinesia Rating Scale, at month six, patients experienced a mean 18% improvement in functional disability during activities of daily living while on oral levodopa. The Parkinson's Disease Questionnaire-39 Summary Index score, a patient and caregiver reported quality of life measure was recorded at baseline, month three and month six. The average score at baseline was 50 points, which at month three had improved to an average score of 31 points. At month 6, the average PDQ-39 Summary Index score was further improved to 18 points. These scores demonstrate an approximate 37% improvement from baseline at month three and an approximate 65% improvement from baseline at month six. These reductions in total score at both three and six months appear to indicate a substantial clinical benefit in this quality of life measure. In addition, a patient-recorded diary was collected again at six months. On average, the patients experienced an improvement from baseline of ON time without dyskinesia of 2.7 hours, a reduction of 2.4 hours in ON time with non-troublesome dyskinesias, a reduction of ON time with troublesome dyskinesias of 1.5 hours, and an increase in OFF time of 0.9 hours. Axovant announced that it has terminated the license and collaboration agreement with Benitec Biopharma in its entirety. This agreement included AXO-AAV-OPMD, in preclinical development for the treatment of oculopharyngeal muscular dystrophy, as well as discovery-stage research collaboration programs including amyotrophic lateral sclerosis, or ALS, and frontotemporal dementia.

07:50 EDT Lithium Americas provides update on project investment by Ganfeng Lithium - Lithium Americas provided an update on the transaction announced April 1, whereby Ganfeng Lithium has agreed to subscribe, through a wholly-owned subsidiary, for newly issued shares of Minera Exar, the holding company for the Cauchari-Olaroz lithium brine project for cash consideration of $160M. Since announcement of the project investment, Lithium Americas and Ganfeng Lithium have been working diligently to satisfy the necessary conditions to closing. The Company has been advised by Ganfeng Lithium that it has received all required regulatory approvals for closing the project investment. BCP Innovation have provided their consent to the project investment. In consideration for providing its consent, in the event the company approves an expansion of the stated production capacity of the project from its current targeted production of 25,000 tonnes per annum, or tpa, to 40,000 tpa, the company will be obligated to provide incremental off-take rights in favour of Bangchak to acquire up to an additional 3,500 tpa of lithium carbonate at market prices. Shareholders of the company and Ganfeng Lithium will be asked to approve the project investment at each company's shareholder meetings, scheduled to be held on June 26 and June 11. In addition to shareholder approval, the project investment remains subject to satisfaction of a number of conditions precedent, including execution of an amended and restated shareholders agreement for Minera Exar, and is expected to close by early Q3. Upon closing of the project investment, Ganfeng Lithium will acquire approximately 141M newly issued shares in Minera Exar, which will increase its interest in Cauchari-Olaroz from 37.5%-50%, with Lithium Americas holding the remaining 50% interest.

07:39 EDT T2 Biosystems T2Bacteria, T2Candida Panels studies published - T2 Biosystems announced the publication of two independent, peer-reviewed studies highlighting the potential of the T2Bacteria and T2Candida Panels to improve outcomes and be cost-effective for a wide range of clinical scenarios. The most recent study was published in the online journal PLOS ONE. This follows another study that was published in the journal Diagnostic Microbiology and Infectious Disease. These studies examined the cost-effectiveness of using two blood culture sets in conjunction with rapid molecular diagnostic assays, including the direct-from-blood T2Bacteria and T2Candida Panels, which are the only FDA cleared diagnostic tests that detect the species-specific pathogens associated with sepsis, versus the use of two sets of blood cultures only, for patients presenting in the emergency department or the medical intensive care unit with severe sepsis or septic shock. The studies concluded that the bundle approach provided more effective antibiotic therapy than blood culture alone. The bundle approach was cost effective as compared to blood culture alone, when considering cost savings for deaths averted by a direct-from-sample molecular diagnostic test. The effectiveness of the bundle approach is expected to maximize when used at time of presentation of septic patients to the emergency department and in hospital settings with high prevalence of drug resistant pathogens and high rates of inappropriate empiric antibiotic therapy. The cost-effectiveness conclusions from the study align with the real-world results reported by T2 customers. This utilization also includes patients that present in the hospital with symptoms of a blood stream infection but are not in severe sepsis or septic shock. The T2Bacteria and T2Candida Panels provide diagnostic results for these patients, allowing clinicians to ensure that their patients are on effective antimicrobial therapy in order to optimize outcomes. These improved clinical outcomes also have the potential to significantly improve cost savings as has been independently demonstrated by many T2 customers.

07:34 EDT Celgene says FDA, EMA, accept applications for ozanimod - Celgene announced that the FDA has accepted for review the New Drug Application for ozanimod for the treatment of people with relapsing forms of multiple sclerosis, or RMS, in the United States. The European Medicines Agency also accepted for review the Marketing Authorization Application for ozanimod for the treatment of adults with relapsing-remitting multiple sclerosis, or RRMS, in the European Union. Ozanimod is an oral, sphingosine 1-phosphate receptor modulator that binds with high affinity selectively to S1P subtypes 1 and 5. Under the Prescription Drug User Fee Act, the FDA has set its action date as March 25, 2020. A regulatory decision from the EMA is expected in the first half of 2020. Both applications are based primarily on ozanimod data from the SUNBEAM and RADIANCE Part B phase 3, multicenter, randomized, double-blind, double-dummy, active-controlled trials.

07:30 EDT FuelCell says Huron will provide various services related to restructuring - FuelCell Energy disclosed last night that on June 2, it entered into an engagement letter with Huron Consulting Services, pursuant to which Huron will provide various services related to the company's restructuring and contingency planning initiatives. In accordance with the engagement letter, the board appointed Laura Marcero, a Managing Director of Huron, as Chief Restructuring Officer of FuelCell and its subsidiaries, and Lee Sweigart, a Senior Director of Huron, as Deputy Chief Restructuring Officer of the company and its subsidiaries. Huron will bill for its services on an hourly basis in the range of $750 to $1025 per hour for Marcero's services, in the range of $685 to $790 per hour for Sweigart's services, and at other ranges depending on the title of the individual providing such services.

07:20 EDT Athenex, PharmaEssentia announce clinical activity signals in KX2-391 study - Athenex and PharmaEssentia announced preliminary clinical activity signals observed in a cohort of patients with psoriasis treated with KX2-391 1% ointment once daily for 5 days in a Phase I clinical trial. Six patients with mild to moderate psoriasis were studied. All patients showed some improvement. One patient had complete resolution of skin scaling and another patient had improvement of psoriatic plaque thickness. The treatment was found to be well-tolerated. Only mild skin burning sensation and irritation were observed in one patient each. Tirbanibulin ointment has been well tolerated in patients with psoriasis and also in trials treating patients with actinic keratosis. Positive topline efficacy and safety results from two Phase III studies of tirbanibulin ointment 1% in the treatment of actinic keratosis were presented at the American Academy of Dermatology in a late breaker oral presentation. Athenex licensed the rights to tirbanibulin to PharmaEssentia for psoriasis and non-malignant skin conditions in Mainland China, Taiwan, Hong Kong, Macau, Singapore and Malaysia, as well as the rights for actinic keratosis in Taiwan. PharmaEssentia is sponsoring this Phase I clinical trial in psoriasis. Athenex also licensed the rights to tirbanibulin for any skin disorder or skin disease in humans, including any skin cancer treated by dermatologists, in the U.S. and European countries, including Russia, to Almirall.

07:15 EDT Athenex voluntarily suspends production at API plant in China - Athenex announced that its active pharmaceutical ingredient, or API, plant in Chongqing, China has voluntarily suspended production activities. The voluntary temporary suspension occurred last month, and the company expects to have a resolution by the end of Q3, subject to inspection and evaluation by the Department of Emergency Management of Chongqing. This voluntary action came after tragic accidents at other chemical plants in March and April in certain provinces of China that led to industry-wide plant inspections focused on production safety. The company has communicated its decision to voluntarily suspend production to its customers. The company plans to continue selling existing API inventories through at least Q3. The company believes that it has sufficient API inventory for all ongoing and near term planned clinical studies and for its registration activities for late-stage clinical products. In addition, the company is in the process of working with its secondary suppliers and securing additional suppliers subject to its needs, as part of normal course supply chain activities. The build-out of the new API plant in Chongqing is near completion and the plant is expected to commence operations in the first half of 2020. Athenex re-affirms its product sales guidance of a 25% to 30% increase in 2019 from the product sales revenue of $56.4M reported in 2018. The decision to voluntarily suspend production activities at the API plant was made to ease concerns from the Department of Emergency Management of Chongqing, which has been evaluating the safety of all chemical and other plants in the region after the recent tragic accidents at other plants in the region. The company believes the API plant has been in compliance from a safety and regulatory perspective. The company will continue to work closely with the department and aims to conclude the inspection as soon as practicable.

07:11 EDT ContraFect awarded $7.2M USAMRDC grant to advance CF-296 - ContraFect announced that the Congressionally Directed Medical Research Programs, or CDMRP, has awarded the company $7.2M in funding from the Military Infectious Diseases Research Program, or MIDRP, United States Army Medical Research and Development Command, or USAMRDC, over the course of three years to advance its lysin candidate, CF-296, through IND-enabling studies after which it may enter the clinic. CF-296 was discovered while the company was working on its platform of direct lytic agents, or DLAs. Lysins, a new class of DLAs, are antimicrobial biologics with a novel mechanism of action which results in the rapid killing of target bacteria, eradication of biofilms and synergy with conventional antibiotics.

07:08 EDT Cubic selected to deliver training support and equipment in Indo-Pacific region - Cubic's Cubic Global Defense business division was awarded several contracts totaling approximately $150M from various customers in the Indo-Pacific region to provide Air Combat Maneuvering Instrumentation, training support for Combat Training Centers and deliver upgrades and maintenance services for the region's live fire ranges. The total value of the awarded contracts includes options to extend as well as support for future overseas exercises and additional services where needed.

07:07 EDT GasLog, GasLog Partners to assume control of vessels operating in spot market - GasLog (GLOG) and GasLog Partners (GLOP) announced a decision to assume commercial control of their vessels currently operating in the LNG carrier spot market through The Cool Pool. The Cool Pool is an LNG carrier pooling agreement between GasLog and Golar LNG (GLNG), focusing exclusively on spot fixtures of up to 12 months in duration. Golar's declared intention to spin off its spot LNG vessels, coupled with the group's belief that robust LNG commodity supply and demand fundamentals will lead to a tightening LNG shipping market and increased multi-year charter opportunities, has led it to decide to withdraw its vessels from The Cool Pool. Assuming commercial control of these vessels will allow the group greater flexibility and agility in pursuing longer-term time charter opportunities. It is anticipated that the five vessels owned by GasLog and the one vessel owned by GasLog Partners currently operating in the spot market will withdraw from The Cool Pool over coming months, based upon current commitments and charter opportunities.

07:04 EDT J.M. Smucker sees FY20 free cash flow $875M-$925M - Sees FY29: CapEx $300M-$320M; Effective tax rate 24.5%-25.0%.

07:02 EDT J.M. Smucker reports Q4 free cash flow $181.6M

06:58 EDT Signet Jewelers backs FY20 CapEx view $135M-$155M

06:55 EDT The Buckle reports May net sales down 1.1% y-o-y to $61.5M - The Buckle reported May comparable store net sales, for stores open at least one year, decreased 0.8% from comparable store net sales for May 2018. Net sales for May decreased 1.1% to $61.5M from net sales of $62.2M for the prior year May period.

06:54 EDT Signet Jewelers CEO says sees 'strong progress on cost savings' - "We delivered operating profit above our guidance range and strong free cash flow in the first quarter, with same store sales at the low end of our guidance," said Signet CEO Virginia Drosos. "Given the sales trends we experienced year to date and softening retail traffic, we are narrowing our Fiscal 2020 guidance while continuing to expect strong progress on cost savings across our business. We remain focused on executing our Path to Brilliance transformation initiatives to improve the trajectory of our same store sales and drive higher profitability over the long-term."

06:37 EDT OncoCyte appoints Ronald Andrews CEO effective July 1st - OncoCyte is appointing current Board member Ronald Andrews as CEO, effective July 1. OncoCyte's current CEO, William Annett, will remain with the company in an advisory role to ensure a seamless transition. Prior to joining OncoCyte as CEO, Andrews was the founder and principal of the Bethesda Group, a company focused on helping organizations in the molecular diagnostics and genomics industries. Before that, he served as the President of the Genetic Science Division for Thermo Fisher Scientific. He sits on the Board of Directors for three companies, both private and public, including the Board of Directors for the American Society of Clinical Oncology's CancerLinq program.

06:34 EDT SAIC reports Q1 contract awards $1.9B - Contract awards for the quarter were $1.9B, including approximately $300M from single-award indefinite-delivery, indefinite-quantity value. Net bookings for the quarter were approximately $1.4B, which reflects a book-to-bill ratio of 0.9. Of the net bookings for the quarter, 70% were for new business. SAIC's estimated backlog of signed business orders at the end of the quarter was approximately $13.6B of which $3B was funded.

06:11 EDT Nordic American Offshore appoints Christopher Avella as CFO - Nordic American Offshore has appointed Christopher Avella as CFO of the company effective June 4, succeeding Bjorn Giver. Avella joins the company from Scorpio Tankers, a related party affiliate, where he has served since 2010 and has held the position of Controller since 2014. Prior to joining Scorpio Tankers, he was with Ernst & Young.

06:05 EDT Global Cord Blood forms special committee to evaluate Cordlife merger proposal - Global Cord Blood announced that in response to the non-binding proposal letter received by the company's board from Cordlife, a company listed on the Mainboard of the Singapore Exchange, pursuant to which Cordlife proposes to combine the businesses of Cordlife and the company by way of a statutory merger, the board has formed a special committee of independent directors who are not affiliated with Cordlife to evaluate such proposal. The special committee consists of Mark Chen, Ken Lu and Jennifer Weng, each of whom currently serves as an independent director on the board, with Chen serving as the chair of the special committee. The special xommittee intends to retain advisors, including an independent financial advisor and U.S. and Cayman Islands legal counsels, to assist it in its evaluation. The company cautions its shareholders and others considering trading its ordinary shares that no decisions have been made with respect to the company's response to the proposed transaction. The proposed transaction is still subject to various conditions, including but not limited to, completion of due diligence, parties entering into definitive agreement, and/or each of Cordlife and the company obtaining its relevant regulatory and shareholders approval. There can be no assurance that any definitive offer will be made, that any agreement will be executed or that this or any other transaction will be approved or consummated.

06:03 EDT Lilis Energy CEO Ron Ormand to retire on June 6, Joe Daches named interim CEO - Lilis Energy announced that Ron Ormand, currently Chairman of the Board of Directors and CEO, has notified the Board of his planned retirement from the company effective June 6. The Board has elected David Wood to serve as Chairman of the Board and Joe Daches, currently President and CFO, to serve as interim CEO while a search for a new CEO is conducted.